WASHINGTON (Reuters) - MedImmune's inhaled vaccine against the pandemic H1N1 virus could be ready to start shipping to the U.S. government by the end of September, a company official said on Thursday.
MedImmune's Dr. Raburn Mallory said the company, a unit of AstraZeneca, has submitted safety data for their nasal spray swine flu vaccine to the U.S. Food and Drug Administration.
"There are no red flags there. We think we can have 5 million doses ready to distribute at the end of September," Mallory said in an interview. U.S. officials had not expected vaccination to begin until mid-October.
(Editing by Sandra Maler)
Trending On Reuters
In a study of 15-year-olds in the U.K., those who had been most exposed to alcohol use in films were also most likely to have tried alcohol, and about twice as likely as the least exposed to have been binge drinking. Full Article